Literature DB >> 1098721

Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation.

.   

Abstract

A combination of mustine, vincristine (Oncovin), procarbazine, and prednisione (MOPP) and the same combination without prednisone (MOP) were compared in the treatment of stage IV Hodgkin's disease in a prospective randomized trial. The complete remission rates were 80% with MOPP and 44% with MOP; the difference was highly significant. Prednisone seems to be an important component of the MOPP combination in the management of stage IV Hodgkin's disease.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1098721      PMCID： PMC1673852          DOI： 10.1136/bmj.3.5980.413

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  6 in total

1.  Lymphosarcoma: a review of 1269 cases.

Authors:  S A ROSENBERG; H D DIAMOND; B JASLOWITZ; L F CRAVER
Journal:  Medicine (Baltimore)       Date:  1961-02       Impact factor: 1.889

2.  The use of steroid hormones in the management of hematologic disorders.

Authors:  W C MOLONEY; S DAVIS; R D HIEBER
Journal:  GP       Date:  1961-07

3.  The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas.

Authors:  H M RANNEY; A GELLHORN
Journal:  Am J Med       Date:  1957-03       Impact factor: 4.965

4.  High-dose corticoid therapy in Hodgkin's disease and other lymphomas.

Authors:  T C Hall; O S Choi; A Abadi; M J Krant
Journal:  Ann Intern Med       Date:  1967-06       Impact factor: 25.391

5.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

6.  Corticosteroids in the treatment of the reticuloses.

Authors:  A M JELLIFFE; J D NABARRO
Journal:  Br J Radiol       Date:  1961-09       Impact factor: 3.039
  6 in total
  4 in total

Review 1.  [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors:  D Huhn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-04-17

2.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06

3.  The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.

Authors:  P J Selby; J L Millar; T A Phelps; M Y Gordon; R Wilkinson; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.

Authors:  R Shepherd; K R Harrap
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.